Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-Lipoic Acid for Prevention of Platinum-Induced Peripheral Neuropathy
NCT00112996Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2007
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alpha-lipoic acid in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2007; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00112996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112996.